• Explore /
  • Poster
  • / Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.

Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.

Abstract Poster

Authors

null

Amelie Anota

Methodology and Quality of Life Unit, Department of Oncology, EA 3181, University Hospital;French National Platform Quality of Life and Cancer, Besancon, France

Amelie Anota , Dewi Vernerey , Christophe Tournigand , Benoist Chibaudel , Benoit Samson , Werner Scheithauer , David Brusquant , Thierry Andre , Aimery De Gramont , Franck Bonnetain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT00265824.

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3553)

DOI

10.1200/JCO.2016.34.15_suppl.3553

Abstract #

3553

Poster Bd #

250

Abstract Disclosures

Similar Posters

First Author: Christophe Tournigand

First Author: Benoit Samson

First Author: Benoist Chibaudel

First Author: Christophe Tournigand